Takeda’s Velcade Patent Overturned in Win for Generics
This article is for subscribers only.
Takeda Pharmaceutical Co. lost a court ruling that could shave years off the time before generic-drug versions of its top-selling cancer drug Velcade hits the market.
A patent on the medicine that expires in 2022 is invalid, U.S. District Judge Gregory Sleet concluded Thursday. He agreed with generic-drug makers who said the patent for a formulation of the drug is “the inherent result of an obvious process.”